当前位置: X-MOL 学术Drug. Discov. Today › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Development and economic trends in anticancer drugs licensed in the UK from 2015 to 2019
Drug Discovery Today ( IF 7.4 ) Pub Date : 2020-11-16 , DOI: 10.1016/j.drudis.2020.11.011
Mark P Lythgoe 1 , Jonathan Krell 1 , Sarah Mahmoud 2 , Emily C Mills 3 , Aishwarya Vasudevan 3 , Philip Savage 3
Affiliation  

Analysis of new anticancer drugs licensed in the UK found that 44 new therapies were approved from 2015 to 2019. No other 5-year period has produced as many new therapies. Most new drugs are kinase inhibitors (KIs, N = 18) and monoclonal antibodies (mAbs, N = 16) with only one classical cytotoxic chemotherapy (CC) licensed. The average median treatment duration has risen by 55 days to 318 days (263 days in 2010–2014). Drug costs have escalated; an average treatment course now costs £62 343, compared to £35 383 in 2010–2014. New drugs are delivering significant clinical benefits with longer treatment durations. However, the financial burden is greater, heralding economic challenges for healthcare providers.



中文翻译:

2015-2019年英国获批抗癌药物发展及经济趋势

对在英国获得许可的新型抗癌药物的分析发现,从 2015 年到 2019 年,批准了 44 种新疗法。没有其他 5 年期间产生了如此多的新疗法。大多数新药是激酶抑制剂(KIs,N  =  18)和单克隆抗体(mAbs,N  =  16),只有一种经典的细胞毒性化疗(CC)获得许可。平均中位治疗持续时间增加了 55 天至 318 天(2010-2014 年为 263 天)。药物成本上升;现在的平均疗程费用为 62 343 英镑,而 2010-2014 年为 35 383 英镑。新药具有显着的临床益处和更长的治疗时间。然而,财务负担更大,预示着医疗保健提供者面临经济挑战。

更新日期:2020-11-16
down
wechat
bug